CTU Bern

CORON-ACT started enrollment

CORON-ACT is a multicenter, double-blind, placebo-controlled phase II trial on the efficacy and safety of tocilizumab in the treatment of progressing coronavirus induced disease (COVID-19). The trial is planned to enroll 100 patients at four Swiss sites and the first site (Inselspital Bern) was opened on April 22nd after only 6 weeks of planning and implementation time. More information on the trial can be found here.